drugset
drugset / Trial / NCT04629287

Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection

NCT04629287 ↗

Phase 1 Unknown 102 enrolled Kunming Pharmaceuticals, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy subjects

Timeline

Start
2020-11
Primary completion
2021-12
Completion
2022-02

Drugs

EvaluationDrugModalityDoseRoute
Subject KPCXM18 Unknown — Intravenous

Indications

No indication recorded.